Skip to main content
Premium Trial:

Request an Annual Quote

Marina Q3 Losses Rise Amid Costs of Restarting Operations


NEW YORK (GenomeWeb) – Marina Biotech today announced its third-quarter financial results, posting a surge in its net loss amid spending related to its resumption of operations.

For the three-month period ended Sept. 30, Marina's net loss was $7.1 million, up from $1 million in the year-ago period. The company attributed the rise to debt extinguishment accounting and increased expenses as it attempts to restart its operations.

In mid-2012, Marina was forced to shut down essentially all of its activities amid a severe cash crunch. Since then, however the company has been able to raise some cash and eliminate certain debt, and is slowly working to resume drug-development efforts.

Operating expenses in the third quarter rose to $170,000 from $100,000 a year earlier, while other expenses jumped to $5.5 million from $1.1 million.

The company reported no revenues in the third quarter.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.